Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2011, Article ID 352686, 5 pages
Research Article

Infliximab Induces Increase in Triglyceride Levels in Psoriatic Arthritis Patients

1Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (CEDMAC), 01246-903 São Paulo, SP, Brazil
2Pediatric Rheumatology Unit, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (CEDMAC), 01246-903 São Paulo, SP, Brazil
3Rheumatology Division, University Hospital of Brasília, Universidade de Brasília, 71660020 Brasília, DF, Brazil
4Disciplina de Reumatologia da FMUSP, Avenidu Dr. Arnaldo, 455, 3 Andar, sala 3190, 01246-903 São Paulo, SP, Brazil

Received 4 January 2011; Revised 19 April 2011; Accepted 27 May 2011

Academic Editor: Berent Prakken

Copyright © 2011 Karla R. Castro et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Objectives. To evaluate lipid profile changes after anti-TNF therapy in patients with psoriatic arthritis (PsA). Methods. Fifteen PsA patients (eight polyarticular, four oligoarticular, two axial, and one mutilating) under infliximab were included. None had dyslipoproteinemia or previous statin use. Total cholesterol (TC) and its fractions, inflammatory markers, and prednisone use were evaluated. Results. The comparisons of lipid levels between baseline and after three months (3M) of anti-TNF therapy showed that there was a significant increase in mean triglycerides ( versus  mg/dL, ) and VLDL-c ( versus  mg/dL, ) levels. In contrast, there were no differences in the mean TC ( ), LDL-c ( ), and HDL-c ( ) levels. Analysis of the frequencies of each lipid alteration at baseline and at 3M were alike ( ). Positive correlations were found between VLDL-c and CRP ( , ) and between triglycerides and CRP ( , ) levels at 3M. ESR reduction was observed after 3M ( ). Mean prednisone dose remained stable at beginning and at 3M ( ). Conclusion. This study demonstrated that anti-TNF may increase TG and VLDL-c levels in PsA patients after three months.